Viemed adds to evidence for NIVH
By HME News Staff
Updated 10:40 AM CDT, Mon September 20, 2021
LAFAYETTE, La. – Patients with COPD and CRF who were prescribed noninvasive ventilation at home had statistically significant reductions in risk of death (38.3%), hospitalizations (21.0%) and ED visits (42.9%) compared with similar patients not treated with NIVH, according to a new study from Viemed Healthcare. The study, which was published Sept. 15 in the online edition of The American Journal of Managed Care, also shows NIVH is associated with a one-year risk difference of 13% for mortality, 8.4% for first hospitalization and 17.6% for first ED visit, yielding relative risk reductions of 30.7%, 12.9% and 20.1%, respectively. “We are very pleased to once again see published evidence that supports the clinical efficacy of NIVH on the highest risk, chronically ill respiratory patients, and are excited to continue to share these results with the medical community,” said Casey Hoyt, Viemed’s CEO. “These results confirm the findings of a separate study published in December 2020, which used different statistical methods and studied a different patient population than that used in the current study.” All data for the study was obtained from the Medicare Limited Data Set and included patients who were diagnosed with COPD and CRF between 2012-17.
Comments